Cache, as a side note on the Mexican market, Mylan's Epipen is not currently being sold there. With a 120M population, there is definitely an large opportunity for a generic epinephrine pen, albeit at somewhat lower profitability than the US market.
Ms Danielle Hobbs is listed as the author of at least the last two corporate presentations (see under PDF "properties"). Any relation to the CEO? Is this the same Danielle Hobbs who is partner at Nfinium? Loko, can you DD this for me? :) Thanks!!
In light of Mylan again raising prices of its Epipen, perhaps it should also be noted that it is part of the FDA's responsibility to "advanc[ing] the public health by helping to speed innovations that make medicines more effective, safer, and more affordable" (from FDA "What We Do").
Teva and Antares have been working for many years to make an AB approvable product. Teva is world-class in this and I highly doubt they'll drop the ball on such a project that will be an important revenue source for them. Needless to say, approval will transform Antares completely and I am betting heavily on that. We will soon find out..